Skip to content
Parker Institute for Cancer Immunotherapy
Search Close

Clinical Trials

Multi-center clinical trials take years to launch, slowing progress. At PICI, we design groundbreaking immunotherapy studies that move forward at the speed of life. Together with leading academic, industry and nonprofit partners, we answer the hard questions in the toughest-to-treat cancers. Always asking why some therapies work while others don’t. Our secret weapon: in-house trials management and translational medicine experts who speed trials from concept to finish line, so that discoveries can benefit cancer patients faster.


Patients treated


Treatment agents studied

What We Do

  • Innovative trial designs. We consistently break the mold on how trials are designed and conducted to accelerate discoveries that benefit patients.
  • Launch trials faster. We streamlined the process to launch multi-center clinical trials to save time and money.
  • Tackle tough cancers. We explore novel treatments for historically hard-to-treat cancers that include tumors of the brain, pancreas and breast.
  • Learn from each patient. Each tissue and blood sample is run through a suite of molecular assays to add to our understanding of cancer biology.
  • Smarter trials. Our first-of-its-kind analysis platform integrates data across our studies and public data to power smarter, science-driven clinical trials.

Meet Our Experts

Clinical Development

Ute Dugan, MD, PhD
Chief Medical Officer


Lacey Padrón, PhD
Head of Informatics

Christine (Chris) Spencer, PhD
Associate Director, Informatics

Research Operations

Christopher Perry
Associate Director, Biospecimen Operations

Clinical Trials

The PORTER Trial

A Study of Novel Combination Therapies for Metastatic Prostate Cancer

The MAHLER Trial

A Study to Explore Patient Response to Checkpoint Inhibitors in Advanced Melanoma

The PRINCE Trial

Pancreatic Cancer: Can a Combination of Immunotherapy and Chemotherapy Defeat It?

The McGRAW Trial

The Microbiome and Cancer: Can Gut Bacteria Help Immunotherapy Destroy Tumors?


Taking Cancer’s Temperature: Biomarkers for Checkpoint Response in Hot vs. Cold Tumors